528 related articles for article (PubMed ID: 30182763)
1. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B.
Mao QG; Liang HQ; Yin YL; Tang JM; Yang JE; Wu CC; Chen Y; Zhang MY; Liu YY; Zheng XT; Zhuang LY; Chen SD
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101758. PubMed ID: 34303003
[TBL] [Abstract][Full Text] [Related]
3. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma.
Jian ZW; Wu XW; Chen ZX; Wang JC; Peng JY; Lao XM
Dig Dis Sci; 2019 Aug; 64(8):2187-2198. PubMed ID: 30815819
[TBL] [Abstract][Full Text] [Related]
4. [Effect of interferon or nucleos(t)ide analogs on hepatitis B-related hepatocellular carcinoma].
Liu ZH; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):842-845. PubMed ID: 31941239
[TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
6. Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB.
Jiang S; Guo S; Huang Y; Xu J; Li Y; Zeng Y; Guo Y; Ouyang L; Zhu C; Zhao W; Zhang Q; Guo Q; Xin H; Xie Q
Antiviral Res; 2024 Jun; 226():105892. PubMed ID: 38663455
[TBL] [Abstract][Full Text] [Related]
7. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
[TBL] [Abstract][Full Text] [Related]
8. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
9. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients.
Hiramatsu N; Yamada R; Takehara T
J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149
[TBL] [Abstract][Full Text] [Related]
10. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
[TBL] [Abstract][Full Text] [Related]
11. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
[TBL] [Abstract][Full Text] [Related]
15. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
Papatheodoridis GV; Lampertico P; Manolakopoulos S; Lok A
J Hepatol; 2010 Aug; 53(2):348-56. PubMed ID: 20483498
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.
Wang Y; Xiang X; Chen L; Cao Z; Bao R; Zhou H; Tang W; Lu J; Lin L; Xie Q; Bao S; Wang H
Oncotarget; 2016 Sep; 7(36):58553-58562. PubMed ID: 27329718
[TBL] [Abstract][Full Text] [Related]
17. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
18. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
[TBL] [Abstract][Full Text] [Related]
19. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
[TBL] [Abstract][Full Text] [Related]
20. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
Han C; Lai PP; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
